Evidence map›Paper›PMID 24849924›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2014

Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice.

Joel E Schlosburg, Steven G Kinsey, Bogna Ignatowska-Jankowska, Divya Ramesh, Rehab A Abdullah, Qing Tao, Lamont Booker, Jonathan Z Long, Dana E Selley, Benjamin F Cravatt and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Anxiety Modulation by Cannabinoids-The Role of Stress Responses and Coping.International journal of molecular sciences · 2023
    Review
  5. Mechanisms of cannabinoid tolerance.Biochemical pharmacology · 2023
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. CBPharmacology, biochemistry, and behavior · 2019
    Article
  16. Article
  17. Review
  18. Cannabinoid CBThe Journal of pharmacology and experimental therapeutics · 2017
    Article
  19. Article
  20. The In Vivo Effects of the CBJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Joel E SchlosburgDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California schlos@scripps.edu.
Steven G KinseyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Bogna Ignatowska-JankowskaDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Divya RameshDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Rehab A AbdullahDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Qing TaoDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Lamont BookerDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Jonathan Z LongDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Dana E SelleyDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Benjamin F CravattDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Aron H LichtmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, Virginia (J.E.S., B.I.-J., D.R., R.A.A., Q.T., L.B., D.E.S., A.H.L.); Department of Psychology, West Virginia University, Morgantown, West Virginia (S.G.K.); and The Skaggs Institute for Chemical Biology and Department of Chemical Physiology (J.Z.L., B.F.C.), and Committee on the Neurobiology of Addictive Disorders (J.E.S.), The Scripps Research Institute, La Jolla, California.
Scripps Research Institute · USVirginia Commonwealth University · USWest Virginia University · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI YAN ZHANG · 2014 to 2026
$13.8M
SYNTHESIS OF SR141716A AND ANANDAMIDE ANALOGSP01DA009789 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI LICHTMAN, ARON H · 1995 to 2013
$11.6M
STRUCTURAL STUDIES OF FAAHP01DA017259 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2004 to 2013
$10.6M
Enzymes That Regulate Fatty Acid Amide Function In VivoR01DA015197 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2002 to 2009
$2.5M
Monoacylglycerol Lipase Inhibitors for Treating Opioid Use Disorders (RO)R01DA032933 · NIDA · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F, LICHTMAN, ARON H · 2012 to 2014
$1.5M
Determining the Role of FAAH and MAGL in the Modulation of Mechanical AllodyniaF31DA028333 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BOOKER, LAMONT · 2010 to 2011
$50k
Endocannabinoid Modulation of PruritusF31DA026279 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI SCHLOSBURG, JOEL EVAN · 2009 to 2009
$30k
NIDA NIH HHS F31 DA026279NIDA NIH HHS F31-DA026279NIDA NIH HHS F31 DA028333NIDA NIH HHS F31-DA028333NIDA NIH HHS P01 DA009789NIDA NIH HHS P01-DA009789NIDA NIH HHS P01 DA017259NIDA NIH HHS P01-DA017259NIDA NIH HHS P30 DA033934NIDA NIH HHS P30-DA033934NIDA NIH HHS R01 DA015197NIDA NIH HHS R01-DA015197NIDA NIH HHS R01 DA032933NIDA NIH HHS R01-DA032933NIDA NIH HHS T32 DA007027NIDA NIH HHS T32-DA007027
6 · The paper itself

Abstract

Complementary genetic and pharmacological approaches to inhibit monoacylglycerol lipase (MAGL) and fatty acid amide hydrolase (FAAH), the primary hydrolytic enzymes of the respective endogenous cannabinoids 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine, enable the exploration of potential therapeutic applications and physiologic roles of these enzymes. Complete and simultaneous inhibition of both FAAH and MAGL produces greatly enhanced cannabimimetic responses, including increased antinociception, and other cannabimimetic effects, far beyond those seen with inhibition of either enzyme alone. While cannabinoid receptor type 1 (CB1) function is maintained following chronic FAAH inactivation, prolonged excessive elevation of brain 2-AG levels, via MAGL inhibition, elicits both behavioral and molecular signs of cannabinoid tolerance and dependence. Here, we evaluated the consequences of a high dose of the MAGL inhibitor JZL184 [4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate; 40 mg/kg] given acutely or for 6 days in FAAH(-/-) and (+/+) mice. While acute administration of JZL184 to FAAH(-/-) mice enhanced the magnitude of a subset of cannabimimetic responses, repeated JZL184 treatment led to tolerance to its antinociceptive effects, cross-tolerance to the pharmacological effects of Δ(9)-tetrahydrocannabinol, decreases in CB1 receptor agonist-stimulated guanosine 5'-O-(3-[(35)S]thio)triphosphate binding, and dependence as indicated by rimonabant-precipitated withdrawal behaviors, regardless of genotype. Together, these data suggest that simultaneous elevation of both endocannabinoids elicits enhanced cannabimimetic activity but MAGL inhibition drives CB1 receptor functional tolerance and cannabinoid dependence.

Indexed as

Adaptation, PhysiologicalAmidohydrolasesAnimalsBenzodioxolesDronabinolEndocannabinoidsFatty Acid Amide HydrolasesMaleMiceMice, Inbred C57BLMice, KnockoutMonoacylglycerol LipasesPiperidinesReceptor, Cannabinoid, CB1AmidohydrolasesBenzodioxolesDronabinolEndocannabinoidsFatty Acid Amide HydrolasesJZL 184Monoacylglycerol LipasesPiperidinesReceptor, Cannabinoid, CB1

Identifiers

PMID24849924
PMCPMC4109488
OpenAlexW1986509856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.